Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Merck & Co., Inc. related to misleading statements about Gardasil sales and is encouraging affected investors to participate in a federal securities class action [2][4]. Group 1: Legal Investigation and Class Action - The law firm is urging investors who suffered losses exceeding $100,000 in Merck between February 3, 2022, and February 3, 2025, to contact them for legal options [1]. - There is an April 14, 2025, deadline for investors to seek the role of lead plaintiff in the class action against Merck [2]. - The complaint alleges that Merck and its executives violated federal securities laws by making false statements regarding Gardasil's expected revenue and demand in China [4]. Group 2: Financial Performance and Market Reaction - Merck reported a 3% decline in GARDASIL/GARDASIL 9 sales, totaling $8.6 billion for the fourth quarter and full year of 2024 [5]. - Following the announcement of the sales decline and a decision to pause shipments of Gardasil into China, Merck's stock price dropped by $9.05 per share, or 9.1%, closing at $90.74 on February 4, 2025 [6].

Core Viewpoint - Merck has entered into an exclusive licensing agreement with Jiangsu Hengrui Pharmaceuticals for the development and marketing of HRS-5346, an investigational oral small-molecule Lipoprotein(a) inhibitor [1][2]. Group 1: Licensing Deal Details - Merck will acquire global rights (excluding Greater China) for HRS-5346, paying an upfront cash payment of $200 million and up to $1.77 billion in milestone payments, along with royalties on future sales [2][3]. - The deal is expected to close in the second quarter, pending customary closing conditions and regulatory approvals [3]. Group 2: Health Implications - Elevated levels of Lipoprotein(a) are a significant risk factor for cardiovascular diseases, affecting approximately 1.4 billion people globally [4]. Group 3: Strategic Context - This licensing agreement marks Merck's third collaboration with Chinese biotech firms, following previous multi-billion dollar deals with Hansoh Pharma and LaNova Medicines [7]. - The strategy aims to diversify Merck's revenue base, which is heavily reliant on Keytruda, accounting for nearly 46% of total revenues in 2024 [8]. - The trend of big pharma companies seeking partnerships in China reflects a broader industry movement towards accessing new drugs at attractive valuations [9].

Core Viewpoint - A class action lawsuit has been filed against Merck & Co., Inc. concerning allegations of securities fraud and unlawful business practices [2][4]. Group 1: Lawsuit Details - The lawsuit involves claims that Merck and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Merck securities during the Class Period have until April 14, 2025, to request to be appointed as Lead Plaintiff [2]. Group 2: Financial Impact - On July 30, 2024, Merck reported a significant reduction in demand for its HPV vaccination Gardasil in China, leading to higher inventory levels and potential shipment shortfalls [4]. - Following this announcement, Merck's stock price dropped by $12.53 per share, or 9.81%, closing at $115.25 per share [5]. - On February 4, 2025, Merck announced it would not meet the previously forecasted $11 billion sales target for Gardasil by 2030, leading to another stock price decline of $9.05 per share, or 9.07%, closing at $90.74 per share [5].

深夜利好！恒瑞医药与默沙东签订19.7亿美元独家 协议 扬子晚报网3月26日讯(记者范晓林实习生朱秋璇)3月25日晚间，中国创新药龙头恒瑞医药 （600276）(600276.SH)宣布与美国跨国药企默沙东(Merck&Co,Inc.股票代码：MRK)达成独家许可协 议，将其自主研发的产品a HRS-5346在大中华区以外的全球权益授予后者。 默沙东将获得HRS-5346在大中华地区以外的全球范围内开发、生产和商业化的独家权利。 公告显示，HRS-5346是一种在研的Lp(a)口服小分子抑制剂，目前正在中国进行二期临床试验。 Lp(a)升高是一种遗传决定的疾病，也是心血管疾病的独立危险因素。据统计，全球约有14亿人口Lp(a) 水平升高。 根据双方敲定的协议条款，在交易款项安排上，恒瑞医药可即刻收获2亿美元的首付款，后续还有 望凭借该项目特定的开发、监管以及商业化进展，获得不超过17.7亿美元的里程碑付款。 若 HRS-5346相关产品顺利获批上市，恒瑞医药还将基于其净销售额，按一定比例获取销售提成， 交易总额上限高达19.7亿美元。HRS-5346作为一款口服小分子Lp(a)抑制剂，目前正在中国国内积极开 ...

Core Viewpoint - HengRui Medicine has entered into a licensing agreement with Merck to develop and commercialize the HRS-5346 project, a significant move in the pharmaceutical industry targeting Lp(a) as a cardiovascular risk factor [1][2]. Group 1: Licensing Agreement Details - The agreement allows Merck exclusive rights to develop, produce, and commercialize HRS-5346 outside Greater China, with an upfront payment of $200 million and potential milestone payments of up to $1.77 billion, plus sales royalties [1]. - The agreement is expected to take effect in the second quarter, but the approval and milestone payment timelines for HRS-5346 remain uncertain [1]. Group 2: Lp(a) and Cardiovascular Disease - Elevated Lp(a) is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD), affecting approximately 1.4 billion people globally, with traditional medications showing limited efficacy in lowering Lp(a) levels [2][3]. - Current treatments, including statins and PCSK9 inhibitors, have limited impact on Lp(a), necessitating the development of targeted therapies [2][3]. Group 3: HRS-5346 and Market Potential - HRS-5346 works by blocking the covalent binding of apolipoprotein(a) with low-density lipoprotein (LDL), significantly reducing Lp(a) levels and improving atherosclerosis risk [3]. - As an oral small molecule drug, HRS-5346 offers better patient compliance and has the potential to become a market breakthrough [3]. Group 4: Industry Trends and Competitors - The development of Lp(a) inhibitors signifies a shift in cardiovascular treatment from broad lipid-lowering strategies to precision-targeted therapies, with several companies, including Novartis and Eli Lilly, advancing their own Lp(a) targeting drugs [4]. - Other domestic companies such as Jingxin Pharmaceutical, Xinlitai, WuXi AppTec, and Shiyao Group are also exploring this target, currently in preclinical stages [4].

港股概念追踪|恒瑞医药与默沙东达成许可协议 港股 创新药"含金量"普遍提升（附概念股） 恒瑞医药公告，公司与默沙东达成协议，将脂蛋白（a）[Lp（a）]口服小分子项目（包括名为HRS-5346 的先导化合物）有偿许可给默沙东，默沙东将获得HRS-5346在大中华地区以外全球范围内开发、生产 和商业化的独家权利。 根据协议，恒瑞授予默沙东在全球范围内（大中华地区除外）开发、生产和商业化HRS-5346的独家权 利。 默沙东将向恒瑞支付2亿美元首付款，恒瑞有资格获得与开发、监管和商业化相关的里程碑付款，最高 可达17.7亿美元。 根据HRS-5346在大中华地区以外的销售情况，默沙东还将向恒瑞支付相应的销售提成。 智通财经APP获悉，自2023年底以来，跨国药企与本土创新药企之间的商务拓展（BD）合作持续升 温，今年更是涌现出多个引人瞩目的合作项目。 今年年初，DeepSeek引爆全球市场，在生物医药领域的创新也颇受华尔街市场关注。 如此也使得，一众跨国药企瞄准研发生产之际，也有不少跨国药企选择探索释放数据、技术和人工智能 的潜力，积极探索与中国本土生物技术公司的合作与伙伴关系，加速数字化布局，寻求新的突破及市场 ...

"心血管疾病在全球存在巨大未满足的临床需求。我们很高兴与心血管领域全球领军企业默沙东达成战略合作，让恒瑞的心血管创新药服务于全球患 者。"恒瑞医药执行副总裁、首席战略官江宁军表示，"相信默沙东卓越的临床研发实力和全球化布局，将加速推动HRS-5346的研发进程。" "血液中Lp（a）升高是动脉粥样硬化性心血管疾病的明确风险因素，影响全球多达五分之一的成年人。"默沙东研究实验室总裁Dean Y.Li博士表 示，"HRS-5346是一种在研的口服小分子Lp（a）抑制剂，将有力拓展并完善我们在心血管、代谢疾病领域的研发管线。" 需要注意的是，该交易的交割取决于能否获得美国《哈特-斯科特-罗迪诺反托拉斯改进法》项下的批准，以及能否满足其他惯常条件。该交易预计于 2025年第二季度完成交割。 19.7亿美元！恒瑞医药出海大消息 创新药龙头恒瑞医药又有出海大动作。 恒瑞医药3月25日晚公告，公司与美国医药巨头默沙东达成协议，将恒瑞的脂蛋白（a）[Lp（a）]口服小分子项目（包括名为HRS-5346的先导化合 物）有偿许可给默沙东，默沙东将获得HRS-5346在大中华区以外的全球范围内开发、生产和商业化的独家权利。 恒瑞医 ...

Group 1 - The Schall Law Firm has initiated a class action lawsuit against Merck & Co., Inc. for alleged violations of the Securities Exchange Act of 1934 [1][4] - The lawsuit pertains to investors who purchased Merck's securities between February 3, 2022, and February 3, 2025, and encourages them to contact the firm before April 14, 2025 [2] - The complaint alleges that Merck made false and misleading statements regarding the demand for its product Gardasil, particularly in China, while concealing negative facts about inventory levels [4] Group 2 - The lawsuit claims that Merck's public statements were materially misleading, leading to investor damages when the truth about the company's situation was revealed [4] - The Schall Law Firm specializes in securities class action lawsuits and represents investors globally [5]

Core Viewpoint - HengRui Medicine has entered into a collaboration with Merck to license its oral small molecule project targeting lipoprotein(a) [Lp(a)], with a maximum transaction value of $1.97 billion [1][2] Group 1: Agreement Details - The agreement allows Merck exclusive rights to develop, manufacture, and commercialize HRS-5346 outside Greater China [1] - HengRui will receive an upfront payment of $200 million and is eligible for up to $1.77 billion in milestone payments related to development, regulatory, and commercialization [1] - The agreement is subject to approval under U.S. regulations and is expected to take effect in the second quarter of 2025 [1] Group 2: Product Information - HRS-5346 is an investigational oral small molecule inhibitor of Lp(a), currently undergoing Phase II clinical trials in China [2] - Elevated Lp(a) levels are a common genetic lipid disorder, affecting over 1.4 billion people globally, and are an independent risk factor for atherosclerotic cardiovascular diseases [2] - Targeting Lp(a) with lipid-lowering therapies represents a significant breakthrough in the prevention and treatment of cardiovascular diseases [2] Group 3: Impact on Company - The signing of this agreement is expected to broaden the overseas market for HRS-5346 and enhance HengRui's innovative brand and international performance [2]

恒瑞医药: 恒瑞医药关于与Merck Sharp & Dohme LLC签署HRS-5346项目授权许可协议的公告 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-029 江苏恒瑞医药股份有限公司 关于与 Merck Sharp & Dohme LLC 签署 HRS-5346 项目授权许可协议的公告 被许可人：Merck Sharp & Dohme LLC （一）许可范围 根据协议，恒瑞授予默沙东在全球范围内（大中华地区除外）开发、生产 和商业化 HRS-5346 的独家权利。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏恒瑞医药股份有限公司（以下简称"恒瑞"或"公司"）与 Merck Sharp & Dohme 公司（以下简称"MSD"或"默沙东"）达成协议，将恒瑞的脂 蛋白（a）Lp（a）口服小分子项目（包括名为 HRS-5346 的先导化合物）有偿 许可给 MSD，MSD 将获得 HRS-5346 在大中华地区以外的全球范围内开发、生产 和商业化的独家权利。 一、许可产品基本信息 HRS-53 ...